Figure 1From: A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer Total progression-free survival in the intention-to-treat population (n = 74). Back to article page